Gene · 9134
Papers2,792
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
181 to 200 of 2,792
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Chondroitin Polymerizing Factor (CHPF) promotes cell proliferation and tumor growth in human osteosarcoma by inhibiting SKP2's ubiquitination while activating the AKT pathway. | Genes Dis | 2023 | 37492722 | PubTator, text mining | PubMed |
CRISPR/Cas9-mediated inactivation of miR-34a and miR-34b/c in HCT116 colorectal cancer cells: comprehensive characterization after exposure to 5-FU reveals EMT and autophagy as key processes regulated by miR-34. | Cell Death Differ | 2023 | 37488217 | PubTator, text mining | PubMed |
| Circular RNAs in hepatocellular carcinoma: biogenesis, function, and pathology. | Front Genet | 2023 | 37485335 | PubTator, text mining | PubMed |
| Upregulation and the clinical significance of KCNQ1OT1 and HAGLROS lncRNAs in papillary thyroid cancer: An observational study. | Medicine (Baltimore) | 2023 | 37478216 | PubTator, text mining | PubMed |
| Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. | Genome Med | 2023 | 37475004 | PubTator, text mining | PubMed |
| Lnc-LRRTM4 promotes proliferation, metastasis and EMT of colorectal cancer through activating LRRTM4 transcription. | Cancer Cell Int | 2023 | 37468908 | PubTator, text mining | PubMed |
| Evaluation of the p53 pathway in polycystic ovarian syndrome pathogenesis and apoptosis enhancement in human granulosa cells through transcriptome data analysis. | Sci Rep | 2023 | 37468508 | PubTator, text mining | PubMed |
| DNMT3A mutation promotes leukemia development through NAM-NAD metabolic reprogramming. | J Transl Med | 2023 | 37464424 | PubTator, text mining | PubMed |
| Retraction Note: circular RNA circ-CSPP1 regulates CCNE2 to facilitate hepatocellular carcinoma cell growth via sponging miR-577. | Cancer Cell Int | 2023 | 37460935 | PubTator, text mining | PubMed |
| Incomplete Recovery from the Radiocontrast-Induced Dysregulated Cell Cycle, Adhesion, and Fibrogenesis in Renal Tubular Cells after Radiocontrast (Iohexol) Removal. | Int J Mol Sci | 2023 | 37446141 | PubTator, text mining | PubMed |
| GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer. | Int J Mol Sci | 2023 | 37446056 | PubTator, text mining | PubMed |
| Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies. | MedComm (2020) | 2023 | 37441462 | PubTator, text mining | PubMed |
| Cyclin E/CDK2 and feedback from soluble histone protein regulate the S phase burst of histone biosynthesis. | Cell Rep | 2023 | 37428633 | PubTator, text mining | PubMed |
| A Syx-RhoA-Dia1 signaling axis regulates cell cycle progression, DNA damage, and therapy resistance in glioblastoma. | JCI Insight | 2023 | 37427593 | PubTator, text mining | PubMed |
| Circular RNA circ-FIRRE interacts with HNRNPC to promote esophageal squamous cell carcinoma progression by stabilizing GLI2 mRNA. | Cancer Sci | 2023 | 37417427 | PubTator, text mining | PubMed |
| A quick and reliable image-based AI algorithm for evaluating cellular senescence of gastric organoids. | Cancer Biol Med | 2023 | 37417294 | PubTator, text mining | PubMed |
| FOXK2 amplification and overexpression promotes breast cancer development and chemoresistance. | bioRxiv | 2023 | 37398114 | PubTator, text mining | PubMed |
| Treatment mechanism of immune triad from the repurposing drug against COVID-19. | Transl Med Aging | 2023 | 37388715 | PubTator, text mining | PubMed |
| CHMP4C as a novel marker regulates prostate cancer progression through cycle pathways and contributes to immunotherapy. | Front Oncol | 2023 | 37388224 | PubTator, text mining | PubMed |
| A novel camptothecin derivative, ZBH-01, exhibits superior antitumor efficacy than irinotecan by regulating the cell cycle. | J Transl Med | 2023 | 37386467 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/9134/papers?page=10